Summary & Overview
CPT 83937: Osteocalcin (Bone Gla Protein) Measurement
CPT code 83937 represents a laboratory assay that quantifies osteocalcin (bone Gla protein, BGP) in serum or plasma to evaluate bone formation and monitor response to bone-building therapies. Nationally, this code is relevant for clinicians managing metabolic bone disease, endocrinologists, rheumatologists, and laboratories that provide specialty bone turnover testing. The test contributes clinical information about bone turnover dynamics and can influence treatment decisions in osteoporosis and other bone disorders.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the clinical context for ordering the test, typical sites of service and service type, and a concise summary of billing considerations tied to this laboratory procedure. The publication provides benchmarks and policy-related context where available, outlines common billing modifiers, and clarifies typical clinical indications for the assay. This summary is intended for a national audience of laboratory administrators, billing professionals, and clinicians who require a clear, concise reference for CPT code 83937 and its role in bone metabolism testing.
Billing Code Overview
CPT code 83937 describes a laboratory measurement of osteocalcin (bone Gla protein, BGP) in serum or plasma. The test quantifies the amount of osteocalcin, a protein involved in bone formation, and is used to assess bone metabolism, bone density status, and response to bone-building drug therapy.
Service type: Clinical laboratory diagnostic test
Typical site of service: Clinical laboratory or hospital laboratory (blood draw performed in outpatient or inpatient settings as needed)
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or an adult receiving treatment for osteoporosis who presents for monitoring of bone formation and response to anabolic or antiresorptive therapy. The clinician orders the osteocalcin (bone G1A protein/BGP) serum test when there is clinical concern about bone turnover, to evaluate therapy response, or when baseline bone formation markers are needed before initiating treatment.
The clinical workflow: the clinician documents diagnosis and indication, places the laboratory order for 83937 in the electronic health record, and provides patient prep instructions (usually no special fasting required). A phlebotomist collects a serum or plasma specimen in the outpatient laboratory, ambulatory clinic, hospital inpatient unit, or reference lab. The lab analyst performs the assay using appropriate instrumentation and reports a quantitative osteocalcin result to the ordering provider. Results are reviewed by the ordering clinician to guide assessment of bone turnover, interpretation with bone mineral density testing, or to monitor response to bone-building drug therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component for the assay if separated from technical work |